Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Chardan Capital

Ocular Therapeutix (NASDAQ:OCUL)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $21.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price target points to a potential upside of 200.43% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday. HC Wainwright upped their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $20.00 price target on shares of Ocular Therapeutix in a report on Monday, December 8th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Ocular Therapeutix Price Performance

OCUL opened at $6.99 on Wednesday. Ocular Therapeutix has a 12-month low of $5.78 and a 12-month high of $16.44. The company has a current ratio of 15.39, a quick ratio of 15.32 and a debt-to-equity ratio of 0.11. The business’s fifty day simple moving average is $11.22 and its 200-day simple moving average is $11.78. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -4.85 and a beta of 0.90.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The firm had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. During the same period in the previous year, the company posted ($0.29) earnings per share. The firm’s quarterly revenue was down 22.4% on a year-over-year basis. On average, equities research analysts anticipate that Ocular Therapeutix will post -0.98 earnings per share for the current fiscal year.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Sanjay Nayak sold 10,348 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $93,545.92. Following the completion of the transaction, the insider owned 332,412 shares of the company’s stock, valued at approximately $3,005,004.48. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Donald Notman sold 11,446 shares of Ocular Therapeutix stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total transaction of $103,471.84. Following the sale, the chief operating officer owned 366,356 shares of the company’s stock, valued at $3,311,858.24. The trade was a 3.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 166,029 shares of company stock valued at $1,498,430 over the last 90 days. Company insiders own 2.30% of the company’s stock.

Institutional Investors Weigh In On Ocular Therapeutix

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Ocular Therapeutix by 26.3% in the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after buying an additional 2,411,953 shares during the period. Avoro Capital Advisors LLC boosted its holdings in shares of Ocular Therapeutix by 5.1% in the 4th quarter. Avoro Capital Advisors LLC now owns 10,777,777 shares of the biopharmaceutical company’s stock valued at $130,842,000 after acquiring an additional 527,777 shares during the last quarter. TCG Crossover Management LLC increased its stake in shares of Ocular Therapeutix by 15.0% in the third quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company’s stock worth $71,510,000 after acquiring an additional 798,084 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in shares of Ocular Therapeutix by 15.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company’s stock worth $56,148,000 after purchasing an additional 620,700 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Ocular Therapeutix by 30.5% during the fourth quarter. Geode Capital Management LLC now owns 4,356,547 shares of the biopharmaceutical company’s stock worth $52,896,000 after purchasing an additional 1,018,094 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Key Stories Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 Phase 3 showed statistical superiority on the trial’s vision endpoint vs Regeneron’s Eylea, supporting Ocular’s plan to pursue an FDA filing — a clear clinical win that could translate into a new wet‑AMD product if regulators and payers agree. Read More.
• Positive Sentiment: Company and coverage note an FDA submission pathway and potential upside to Ocular’s product mix if AXPAXLI (SOL‑1) secures approval — this is the strategic bull case for longer‑term investors. Read More.
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the raw data are positive but market is parsing subgroup analyses, comparator details and next regulatory steps before re‑rating the stock. Read More.
• Negative Sentiment: Despite the Phase 3 win, coverage highlighted the observed clinical benefit as modest and noted that some comparisons used a lower‑dose/less favorable version of Eylea — investors questioned meaningful commercial differentiation, prompting large intraday selling. Read More.
• Negative Sentiment: Multiple insiders sold shares on Feb. 12 (notably Pravin Dugel sold 124,882 shares at ~$9.04, and several executives sold smaller blocks), which can sap market confidence even when sales may be routine or for diversification. Read More. Read More.
• Negative Sentiment: Recent quarter: EPS beat per‑share loss estimate but revenue missed and the company remains unprofitable with negative margins — factors that increase sensitivity to commercialization risk and funding needs. Read More.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.